Obesity is a chronic, relapsing, progressive disease. It is identified by abnormal and excessive fat accumulation which is defined as a body mass index (BMI) higher than 25 kg/m 2 . 1 The health risks of obesity include a wide range of medical, surgical, gynecological, obstetric, social, and psychological conditions such as hypertension, cerebrovascular incidents, cancers, hyperlipidemia, coronary heart disease, diabetes mellitus, and degenerative arthritis.
increases the small intestinal lipid metabolism by activating the long-chain acyl-CoA synthetase (ACSL3) pathway, which regulates whole-body glucose homeostasis in the body. 13 The suppression of lipid absorption in the small intestine in the presence of L. gasseri has been reported. 14 Inflammation in the intestine is correlated with obesity. Supplementing IL-10-deficient mice with L. gasseri (NC1501) for 4 weeks significantly reduced inflammation by producing MnSOD, which is associated with a reduction in the infiltration of neutrophils and macrophages. 15 The immune-modulatory properties of L. gasseri have been confirmed. 16 Lactobacillus gasseri SF1183 produces a molecule which interferes with the proliferation of human intestinal HCT116 cells and has anti-apoptotic activity and cytostatic effects on epithelial colon cells. The protective effect of L. gasseri against apoptosis of intestinal epithelial cells in the presence of inflammatory cytokines is caused by cell cycle arrest. 17 L. gasseri (SBT0270) increased the number of fecal Lactobacilli without affecting the number of fecal coliforms. Changing the gut's microbiota was associated with hypocholesterolemic effects (reductions in total cholesterol, HDL, LDL, and triglycerides) in hypercholesterolemic rats. Food intake was significantly decreased in the presence of L. gasseri. 18 L. gasseri ATCC 33323 exhibited protective effects against tetracyclineinduced body fat accumulation in a rat animal model. 19 All evidence emphasized the efficiency of L. gasseri on the subject of obesity. Because the effect of probiotics in weight loss is species-and strain-specific and L. gasseri L66-5 promotes weight gain, 20 the efficiency of the L. gasseri strain on weight loss was determined in detail.
Lactobacillus gasseri SBT2055
Animal Study on the Efficacy of Lactobacillus gasseri SBT2055 in Obesity The administration of L. gasseri SBT2055 (6×10 7 CFU/g) for 4 weeks in male Sprague-Dawley rats significantly decreased the average adipose size in mesenteric white adipose tissue (P = 0.004), serum leptin (P = 0.031), and liver triacylglycerol levels (P = 0.009); it further increased the number of small adipocytes from mesenteric (P = 0.004) and retroperitoneal (P = 0.053) adipose tissue. Neither adiponectin concentrations, serum glucose, serum and liver lipids, body and liver weight, nor adipose tissue were affected by a diet with L. gasseri. 21 A significant reduction in adipocyte size in Sprague-Dawley rats was reported after the animals consumed a diet which included fermented skimmed milk (SM) containing L. gasseri SBT2055 (6×107 CFU/g). Reductions in subcutaneous adipose tissue weight (P < 0.05), adipocyte size (P < 0.001), and serum leptin concentration (P < 0·05) in lean Zucker rats were observed after feeding them a diet containing L. gasseri for 4 weeks. L. gasseri had no effect on the mesenteric adipose tissue of obese Zucker rats, but the number of small adipocytes in the subcutaneous adipose tissue and lipoprotein lipase activity in adipose tissue of obese rats increased (P < 0.05). L. gasseri significantly reduced the concentration of serum leptin in both obese and lean Zucker rats, and it had no effect on serum glucose and adiponectin levels of Zucker rats. A significant reduction in serum and hepatic HDL-cholesterol and increases in the excretion of fecal fatty acids and total neutral fecal sterols were observed in both lean and obese Zucker rats. L. gasseri reduced the maximum transport rate of triacylglycerol, phospholipids, and lymphatic lipid absorption in the cannulated thoracic lymph ducts of Sprague-Dawley rats.
14 Yogurt containing L. gasseri SBT2055 (5×10 8 CFU/g) consumed for 4 weeks inhibited the enlargement of visceral adipocytes and sICAMI as the inflammatory marker gene in obese male Sprague-Dawley rats. 22 The body weight, fat tissue mass, and triglyceride levels of the liver were significantly decreased after feeding a 10% fat diet containing L. gasseri LG2055 (2.5 ×10 8 ) for 24 weeks to C57BL/6 mice. L. gasseri inhibited the pro-inflammatory genes in epididymal adipose tissue and liver lipogenic genes, improved the inflammatory condition in adipose tissue, and exhibited anti-obesity effects. 23 Leptin expression and its release are closely linked with adipose size 24 ; leptin regulates the fat synthesis and distributes and modulates hepatic β-oxidation, which inhibits hepatic triacylglycerol accumulation. Adipose tissue expansion is associated with an increase in fat cell size or cell number. 25 Animal studies on the anti-obesity effects of L. gasseri SBT2055 have exhibited improvement in inflammatory conditions, a reduction in leptin, a reduction in the size of adipose cells and an increase in their number, and the excretion of fatty oil in the feces of animals, which help the anti-obesity effects of L. gasseri SBT2055; however, the colony-forming unit of cells is about 2. 2 were compared with a placebo group (n=44). The results showed a significant reduction in abdominal visceral and subcutaneous fat areas (4.6% and 3.3%) (P < 00.01), body weight (1.4%) (P < 00.001), BMI (1.5%), waist (1.8%), and hip (1.5%) circumferences for the intervention group compared with baseline. No changes in these parameters were observed for the placebo group. 26 Another single blind controlled trial was performed on 20 Japanese hypertriacylglycerolemia subjects. Initially, the subjects took 200 g/d fermented milk for 4 weeks (placebo group), and after a 4-week washout period, they received fermented milk containing 10 11 CFU/day L. gasseri SBT2055. At the end of each week, 8-hour intake of oral fat loading test meals were fed. Blood samples were taken at fasting and every hour for 8 hours, and the postprandial serum non-estrified fatty acid, triacylglycerol, and fasting blood parameters were evaluated. The postprandial non-sterified fatty acid level was significantly reduced after consumption of yogurt containing L. gasseri LG2055. Anthropometric parameters (body weight, BMI, waist), insulin, glucose, triacylglycerol, total cholesterol, HDL, LDL, and liver enzymes (ALP, AST, ALT) showed no significant differences between the two groups. HbA1 levels were significantly greater in the probiotic group than in the placebo group. No adverse effects were observed during the study. The results of the study suggest its efficacy in reducing the risk of diseases such as obesity and type 2 diabetes. 27 The study was limited by the number of volunteers enrolled in it.
A multi-center, double-blind, parallel-group randomized clinical trial was conducted on 210 healthy Japanese adults with large visceral fat areas (80.2-187.8 cm 2 ). The subjects were randomly divided into three groups and fed 200 g of fermented milk containing 2×10 9 , 2×10
8 , or 0 CFU L. gasseri SBT2055 for 12 weeks. The abdominal visceral fat areas changed 28.5% (P < 0.01) and 28.2% (P < 0.01) in the 2×10 9 and 2×10 8 groups, respectively. BMI, waist and hip circumferences were significantly reduced in both L. gasseri groups at weeks 8 and 12 from baseline, while no reduction was observed in the placebo group. There was a significant difference in BMI at week 12 in both probiotic groups compared with the placebo group. A significant reduction in fat mass was observed at week 12 from baseline in both probiotic groups compared with the control. No adverse events related to the consumption of probiotics were observed during the study. No physiologically significant changes or blood biochemical changes in triacylglycerol, total cholesterol, LDL cholesterol, HDL cholesterol, non-esterified fatty acids (NEFAs), total ketone bodies, lipoprotein, blood glucose, HbA1c, insulin, AST, ALT, ALP, L-lactate dehydrogenase, total protein, albumin, uric acid, blood urea N, creatinine, Na, Cl, K, Ca, P, Mg, Fe, leucocytes, erythrocytes, Hb, hematocrit, or platelets were observed; all parameters were in normal ranges. 28 The results of clinical studies showed that 2×10 11 L. gasseri SBT2055 from human fecal sources is a valuable probiotic bacterium for weight loss.
Mechanisms of Anti-obesity Effects of Lactobacillus gasseri SBT2055 Different mechanisms are involved in the anti-obesity effects of L. gasseri SBT2055. It has been confirmed that Ccl2 gene expression was inhibited by L. gasseri SBT2055 in dietinduced obese mice, which is associated with weight loss. Ccl2 gene express CC chemokine ligand 2, which infiltrates the macrophages into the adipose tissue. Administration of male mice C57BL/6J with normal, high-fat (control) and high-fat diets plus L. gasseri SBT2055 (1×10 9 CFU/g) for 12 weeks, showed L. gasseri had no effects on abdominal fat weight and body weight, but L. gasseri significantly reduced the macrophages and the ratio of M1 macrophages as activated inflammatory macrophages to total macrophages in adipose tissues. The expression of Ccl2, Ccr2 and Lep genes were significantly reduced after the administration of L. gasseri SBT 2055. 29 L. gasseri SBT 2055 for 21 weeks exerted anti-inflammatory and protective effects against intestinal barriers in high fat fed-C57BL/6 mice. Body weights and mesenteric and perirenal/retroperitoneal adipose tissues were significantly lower in the mice given L. gasseri SBT 2055 compared with the high fat-fed mice. L. gasseri SBT 2055 increased the number of M2 macrophages and decreased the M1:M2 ratio compared with the high fat-fed mice, which implies an improvement in an inflammatory condition of the body. A reduction in CD8+ T cells in adipose cells was observed after administration of L. gasseri LG2055. The permeability of the intestine in high fat-fed mice was reduced in the presence of L. gasseri, which improved the barrier functions, and these changes in gut permeability are related to adipose tissue inflammation. A reduction in intestine permeability is associated with a reduction in LPS or other inflammatory cytokines. 30 IL-10 production is stimulated by dendritic cells in the presence of L. gasseri SBT2055 31 and partly increases the population of M2 macrophages in adipose tissue. 30 The effects of L. gasseri SBT2055 on fat lipolysis was evaluated in vitro by evaluating the pancreatic lipase activity test. The effects of 100 g fermented milk containing L. gasseri (n=15) was compared with fermented milk without L. gasseri (5×10 9 CFU) (n=15) on fecal fat excretions in healthy subjects (27-69 years old) in a double-blind, randomized, controlled clinical study. L. gasseri showed dose-dependent inhibitory effects against lipase activity and significantly increased the fecal fat concentration compared with the placebo group. L. gasseri suppressed lipid absorption in the small intestine. Triacylglycerol is hydrolyzed by pancreatic lipase in the duodenum. Therefore, inhibition of pancreatic lipase is the main strategy in controlling obesity. Direct inhibition of pancreatic lipase was not confirmed by L. gasseri LG2055, because it cannot use 4-MUO (methylumbelliferyl oleate) as a substrate. L. gasseri increased the fat droplet size which, along with specific surface area, can affect its digestion and absorption. By modifying fat emulsion properties, L. gasseri suppressed lipid digestion and absorption. The interaction between bile acid and L. gasseri SBT2055 increased the fat droplet size, which is associated with low absorption and digestion. BMI and total serum cholesterol concentration were significantly decreased in both the control and the active groups. 32 The protective effects of L. gasseri SBT2055 against oxidative stress in mammalian cells were confirmed. Up-regulation of the Nrf2 protein and its nuclear translocation activates the Nrf2-antioxidant response element (ARE) signaling pathway as the result of JNK activation in L. gasseri SBT2055-treated mammalian cells. The activation of the Nrf2-ARE pathway (JNK-dependent Nrf2-ARE signaling pathway) by L. gasseri strengthens the mammalian cells against oxidative stress.
33
The lifespan of Caenorhabditis elegans was extended after feeding with L. gasseri LG2055 through activation of the Nrf2 ortholog, SKN-1, p38MAPK signaling pathway, and the defense system against oxidative stress.
34
Oral administration of L. gasseri SBT2055 in mice increased the population of IgA + cells in Peyer's patch and in the lamina propria of the small intestine, which is associated with IgA production. A significant increase in IgA production was observed in a co-culture of B cells and dendritic cells from bone marrow. TLR2 signal is critical for IgA production. In addition, it has been demonstrated that L. gasseri SBT2055 stimulates BMDC to promote TGF-β, BAFF, IL-6, and IL-10 production, which are critical to the production of IgA from B-cells. IgA has a critical role in the host defense against mucosal pathogens.
35 Its anti-inflammatory and antioxidant effects on fat droplet size, absorption, and digestion, and its inhibitory effects against pancreatic lipase are mechanisms that may be involved in the anti-obesity effects of L. gasseri SBT2055.
Lactobacillus gasseri BNR17
Animal Study on Efficacy of Lactobacillus gasseri BNR17 in Obesity Lactobacillus gasseri BNR17 is isolated from human breast milk. L. gasseri BNR17 (10 9 CFU), with no effect on daily food intake, reduced the percentage of increase in body weight (P = 0.0331), fat pad mass (P < 0.01), and white adipose tissue mass in rats fed a high-carbohydrate diet twice daily for 12 weeks. L. gasseri BNR17 had no significant effect on total cholesterol, HDL cholesterol, triglycerides, total protein, LDL cholesterol, kidney or spleen weight. L. gasseri reduced blood glucose levels and had protective effects against obesityinduced hepatomegaly through microvesicular steatosis, fibrosis, and sinusoidal dilation. 36 The effects of L. gasseri BNR17 (10 7 , 10
) for 12 weeks in db/db mice showed that the food intake, water intake, and amount of excrement decreased dose-dependently. Body weight was not reduced in the BNR17 groups. Fasting and postprandial blood glucose levels were significantly reduced after the administration of L. gasseri BNR17. An insignificant reduction in HbA1c was observed in the BNR17 groups.
37 C57BL/6J mice supplemented with a high sucrose diet containing L. gasseri BNR17 (10 9 or 10 10 CFU) for 10 weeks showed a significant reduction in body weight, subcutaneous and abdominal fat mass, and white adipose tissue weight compared with mice on a normal diet. L. gasseri BNR17 is associated with increases in mRNA levels of fatty acid oxidation-related genes (ACO, CPT1, PPARa, PPARd), GLUT4 (main glucose transporter-4), and reductions in fatty acid synthesis-related genes (SREBP-1c, ACC), leptin, and insulin compared with the high-sucrose-diet group. 38 The results of animal studies on the effects of L. gasseri BNR17 on obesity are promising but need more evaluation in clinical studies.
Clinical Study on Efficacy of Lactobacillus gasseri BNR17 in Obesity The efficacy of L. gasseri BNR17 (n=23) on obese adults (19-60 years old) with a BMI higher than 23 kg/m 2 and a fasting blood sugar higher than 100 mg/dL for 12 weeks was compared with a placebo group of adults (n=29), and the body fat, body weight, and waist and hip circumferences were evaluated. Patients took 6 capsules of probiotic cells (10 10 CFU), 3 times a day. Although a slight reduction in body weight and a significant reduction in BMI, hip and waist circumferences were observed in the probiotic group compared with its baseline, the difference between the two groups was not significant. No significant differences were noted in fat or muscle amount, BMI, visceral adipose tissue, or deep adipose tissue between the two groups after interventions. Vital symptoms including systolic and diastolic blood pressure and pulse rate showed no significant difference between the two groups. Fasting blood sugar, 2PPBS, HbA1c, insulin, total cholesterol, HDL, LDL, and triglyceride levels had no significant differences between the two groups. Blood chemistry parameters were not affected by the intervention. The only significant reduction observed was seen in hematocrit in the probiotic group (P = 0.02). No serious adverse effects were observed during either of the treatments. 39 Lactobacillus gasseri BNR17 in low (10 9 CFU/day) (n=30) and high doses (10 10 CFU/day) (n=30) was evaluated for its anti-obesity effects on 90 obese volunteers (20-75 years old) with BMIs of 25-35 kg/m 2 for 12 weeks in a randomized, double-blind, placebo controlled study. No adverse effects were recorded during the study, and the mean compliance ratio was 94%. Anthropometric measures and demographic properties other than gender, waist circumference, and waistto-hip ratio were not significantly different among the three groups at baseline. Means of body weight, BMI, waist and hip circumferences had no significant difference after 12 weeks of treatment. The waist circumference was reduced and visceral adipose tissue was significantly reduced in the high probioticdose group. Biochemical parameters (total cholesterol, HDL, LDL, total glycerol, fasting blood glucose, insulin, leptin, adiponectin, CR) had no significant differences among the three groups. 40 Although the daily dose of L. gasseri BNR17 was lower than that of L. gasseri SBT2055, the results on weight loss are hopeful.
Conclusions
The prevalence of obesity has been increasing in the world and is associated with many fatal diseases. Measures to prevent and treat obesity are vital. The side effects of drugs limit their applications; therefore, consumers prefer to use natural treatments, like medicinal plants and other sources. Probiotics are live, beneficial bacteria which have many functional properties in the body. L. gasseri is one well-known probiotic known for its weight loss properties. L. gasseri is used in many commercial, natural products for weight loss. In this review article, the use of two main strains, L. gasseri SBT2055 and BNR17, were discussed. The source of BNR17 is different from that of SBT2055. Although animal and clinical studies have been performed on both, there are more results and comprehensive studies on SBT2055. It is certain that the weight loss effects of L. gasseri are strain-sensitive, and the strain is very important in weight loss products. L. gasseri also improved inflammatory conditions in adipocyte tissue and the intestine, and helps the body resist oxidative stress. It increases fat droplet size and reduces their absorption and digestion. Furthermore, they deconjugate bile acids, which increases the excretion of fat and sterols in human feces. L. gasseri inhibits pancreatic lipase, reduces serum leptin, and increases the number of small adipocyte tissues in the body. It also inhibits the growth of adipocyte tissue in the body. By these mechanisms, specific strains of L. gasseri are good candidates for weight loss.
